- Home
- ANSC vs PGEN Comparison
ANSC vs PGEN Comparison
Compare ANSC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANSC
- PGEN
- Stock Information
- Founded
- ANSC 2021
- PGEN 1998
- Country
- ANSC United States
- PGEN United States
- Employees
- ANSC N/A
- PGEN N/A
- Industry
- ANSC
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ANSC
- PGEN Health Care
- Exchange
- ANSC Nasdaq
- PGEN Nasdaq
- Market Cap
- ANSC 463.6M
- PGEN 404.4M
- IPO Year
- ANSC 2023
- PGEN N/A
- Fundamental
- Price
- ANSC $10.76
- PGEN $1.33
- Analyst Decision
- ANSC
- PGEN Strong Buy
- Analyst Count
- ANSC 0
- PGEN 4
- Target Price
- ANSC N/A
- PGEN $7.33
- AVG Volume (30 Days)
- ANSC 83.0K
- PGEN 1.8M
- Earning Date
- ANSC 01-01-0001
- PGEN 05-14-2025
- Dividend Yield
- ANSC N/A
- PGEN N/A
- EPS Growth
- ANSC N/A
- PGEN N/A
- EPS
- ANSC 0.19
- PGEN N/A
- Revenue
- ANSC N/A
- PGEN $4,201,000.00
- Revenue This Year
- ANSC N/A
- PGEN $189.12
- Revenue Next Year
- ANSC N/A
- PGEN $1,093.07
- P/E Ratio
- ANSC $56.23
- PGEN N/A
- Revenue Growth
- ANSC N/A
- PGEN N/A
- 52 Week Low
- ANSC $10.23
- PGEN $0.65
- 52 Week High
- ANSC $10.78
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- ANSC 72.90
- PGEN 45.09
- Support Level
- ANSC $10.73
- PGEN $1.28
- Resistance Level
- ANSC $10.74
- PGEN $1.41
- Average True Range (ATR)
- ANSC 0.00
- PGEN 0.11
- MACD
- ANSC -0.00
- PGEN 0.00
- Stochastic Oscillator
- ANSC 100.00
- PGEN 25.93
About ANSC Agriculture & Natural Solutions Acquisition Corporation
Agriculture & Natural Solutions Acquisition Corp is a blank check company.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.